Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/161563
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZarei, Mohammad-
dc.contributor.authorPizarro Delgado, Javier-
dc.contributor.authorBarroso Fernández, Emma-
dc.contributor.authorPalomer Tarridas, Francesc Xavier-
dc.contributor.authorVázquez Carrera, Manuel-
dc.date.accessioned2020-05-20T08:52:20Z-
dc.date.available2021-01-26T06:10:19Z-
dc.date.issued2020-01-26-
dc.identifier.issn0165-6147-
dc.identifier.urihttp://hdl.handle.net/2445/161563-
dc.description.abstractNonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis with inflammation, hepatocyte injury, and different degrees of fibrosis. Although NASH affects 2-5% of the global population, no drug has been specifically approved to treat the disease. Fibroblast growth factor 21 (FGF21) and its analogs have emerged as a potential new therapeutic strategy for the treatment of NASH. In fact, FGF21 deficiency favors the development of steatosis, inflammation, hepatocyte damage, and fibrosis in the liver, whereas administration of FGF21 analogs ameliorates NASH by attenuating these processes. We review mechanistic insights into the beneficial and potential side effects of therapeutic approaches targeting FGF21 for the treatment of NASH.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier Current Trends-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.tips.2019.12.005-
dc.relation.ispartofTrends in Pharmacological Sciences, 2020, vol. 41, num. 3, p. 199-208-
dc.relation.urihttps://doi.org/10.1016/j.tips.2019.12.005-
dc.rightscc-by-nc-nd (c) Elsevier Current Trends, 2020-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)-
dc.subject.classificationInflamació-
dc.subject.classificationTriglicèrids-
dc.subject.classificationMalalties del fetge-
dc.subject.classificationObesitat-
dc.subject.otherInflammation-
dc.subject.otherTriglycerides-
dc.subject.otherLiver diseases-
dc.subject.otherObesity-
dc.titleTargeting FGF21 for the treatment of nonalcoholic steatohepatitis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec699717-
dc.date.updated2020-05-20T08:52:20Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
699717.pdf722.79 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons